KRAS and colorectal cancer: A recent study found that the combination of the MDM2–p53 interaction inhibitor (SAR405838) and mitogen-activated protein kinase (MEK) inhibitor (Pimasertib) increases the PUMA and Bcl-2-like protein 11 (BIM) proteins level and leads to cell growth inhibition and apoptosis induction in KRAS mutant and TP53 wild-type non-small cell lung cancers and colorectal cancer models [106].